Velarion · Company Intelligence
Compensation Brief
Fiscal year 2024 · Filings through 2026-07-22

Biolife Solutions Inc (BLFS)

Fiscal year 2024 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$7,046,205
Roderick de Greef total, FY2024
53rd
CEO pay percentile vs peers
58:1
CEO-to-median pay ratio
94.71%
Say-on-pay support, latest vote
Companies that benchmark against BLFS
7 companies name BLFS as a compensation peer

Each company listed discloses BLFS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named BLFS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2024

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Roderick de Greef$744,450$0$5,571,874$0$655,116$0$74,765$7,046,205
Chief Executive Officer and Chairman of the Board
Troy Wichterman472,00001,820,4430249,216012,3482,554,007
Chief Financial Officer
Aby Mathew435,00001,111,5110172,260014,7231,733,494
Executive Vice President and Chief Scientific Officer
Karen Foster430,0000901,2100170,280013,6491,515,139
Chief Quality and Operations Officer
Garrie Richardson317,4790651,833000417,9761,387,288
Former Chief Revenue Officer
Todd Berard336,3730630,8600148,004012,2581,127,495
Chief Commercial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2024 totalFY2023 totalFY2022 totalΔ FY20232024
Roderick de Greef$7,046,205$5,316,798$2,383,673+1,729,407
Troy Wichterman2,554,0071,697,2211,754,856+856,786
Aby Mathew1,733,4941,345,6881,699,295+387,806
Karen Foster1,515,1391,122,8771,344,852+392,262
Garrie Richardson1,387,288
Todd Berard1,127,495

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Sean WernerChief Technology Officer2025-07-18D1,115$21$23,660CommonForm 4 ↗
Casdin Partners Master Fund, L.P.Greater-than-10% holder2025-08-11D500,0002311,300,000CommonForm 4 ↗
Casdin Partners Master Fund, L.P.Greater-than-10% holder2025-08-15D500,0002412,200,000CommonForm 4 ↗
Todd BerardChief Marketing Officer2025-08-25D10,00026255,300CommonForm 4 ↗
Sarah AebersoldChief Human Resources Officer2025-08-26D219255,571CommonForm 4 ↗
Troy WichtermanChief Financial Officer2025-08-26D5902515,010CommonForm 4 ↗
Aby MathewEVP & Chief Scientific Officer2025-08-26D5312513,509CommonForm 4 ↗
Todd BerardChief Marketing Officer2025-08-26D354259,006CommonForm 4 ↗
Karen FosterChief Quality and Operations2025-08-26D4132510,507CommonForm 4 ↗
Sean WernerChief Technology Officer2025-08-26D111252,824CommonForm 4 ↗
Troy WichtermanChief Financial Officer2025-09-11D1,0322727,689CommonForm 4 ↗
Todd BerardChief Marketing Officer2025-09-11D358279,605CommonForm 4 ↗
Sarah AebersoldChief Human Resources Officer2025-09-11D233276,251CommonForm 4 ↗
Aby MathewEVP & Chief Scientific Officer2025-09-11D6302716,903CommonForm 4 ↗
Sean WernerChief Technology Officer2025-09-11D72271,932CommonForm 4 ↗
Karen FosterChief Quality and Operations2025-09-11D5112713,710CommonForm 4 ↗
Sarah AebersoldChief Human Resources Officer2025-09-15D7142618,286CommonForm 4 ↗
Troy WichtermanChief Financial Officer2025-10-09D8332722,791CommonForm 4 ↗
Todd BerardChief Marketing Officer2025-10-09D289277,907CommonForm 4 ↗
Karen FosterChief Quality and Operations2025-10-09D4192711,464CommonForm 4 ↗
Aby MathewEVP & Chief Scientific Officer2025-10-09D5092713,926CommonForm 4 ↗
Sarah AebersoldChief Human Resources Officer2025-10-09D188275,144CommonForm 4 ↗
Casdin Partners Master Fund, L.P.Greater-than-10% holder2025-10-15D750,0002921,410,325CommonForm 4 ↗
Joydeep GoswamiDirector2025-10-16D1,334CommonForm 4 ↗
Sean WernerChief Technology Officer2025-10-20D275287,651CommonForm 4 ↗
Roderick de GreefDirector2025-10-22D37,795271,031,804CommonForm 4 ↗
Joydeep GoswamiDirector2025-10-24D1,6662948,297CommonForm 4 ↗
Roderick de GreefDirector2025-11-11D35,41726926,155CommonForm 4 ↗
Roderick de GreefDirector2025-11-11D33,41826864,858CommonForm 4 ↗
Roderick de GreefDirector2025-11-11D31,16525789,409CommonForm 4 ↗
Amy DuRossDirector2025-11-19D4772511,687CommonForm 4 ↗
Amy DuRossDirector2025-11-19D4,52325110,859CommonForm 4 ↗
Amy DuRossDirector2025-11-19D1,0002626,000CommonForm 4 ↗
Karen FosterChief Quality and Operations2025-11-25D4152711,097CommonForm 4 ↗
Aby MathewEVP & Chief Scientific Officer2025-11-25D5262714,065CommonForm 4 ↗
Amy DuRossDirector2025-11-25D2,0002754,000CommonForm 4 ↗
Sarah AebersoldChief Human Resources Officer2025-11-25D217275,803CommonForm 4 ↗
Todd BerardChief Marketing Officer2025-11-25D351279,386CommonForm 4 ↗
Sean WernerChief Technology Officer2025-11-25D110272,941CommonForm 4 ↗
Troy WichtermanChief Financial Officer2025-11-25D5842715,616CommonForm 4 ↗
Amy DuRossDirector2025-11-25D2,0002754,000CommonForm 4 ↗
Troy WichtermanChief Financial Officer2025-12-04D30,00026771,600CommonForm 4 ↗
Sarah AebersoldChief Human Resources Officer2025-12-09D7132417,440CommonForm 4 ↗
Karen FosterChief Quality and Operations2025-12-09D5192513,042CommonForm 4 ↗
Troy WichtermanChief Financial Officer2025-12-09D1,0332525,959CommonForm 4 ↗
Aby MathewEVP & Chief Scientific Officer2025-12-09D6312515,857CommonForm 4 ↗
Sarah AebersoldChief Human Resources Officer2025-12-09D233255,855CommonForm 4 ↗
Todd BerardChief Marketing Officer2025-12-09D358258,997CommonForm 4 ↗
Amy DuRossDirector2025-12-15D2,0002549,200CommonForm 4 ↗
Karen FosterChief Quality and Operations2026-01-06D335268,573CommonForm 4 ↗
Aby MathewEVP & Chief Scientific Officer2026-01-06D4052610,364CommonForm 4 ↗
Todd BerardChief Marketing Officer2026-01-06D344268,803CommonForm 4 ↗
Sarah AebersoldChief Human Resources Officer2026-01-06D241266,167CommonForm 4 ↗
Troy WichtermanChief Financial Officer2026-01-06D9902625,334CommonForm 4 ↗
Roderick de GreefDirector2026-02-24A170,291CommonForm 4 ↗
Karen FosterChief Quality and Operations2026-02-24A32,112CommonForm 4 ↗
Amy DuRossDirector2026-02-24A8,170CommonForm 4 ↗
Sean WernerChief Technology Officer2026-02-24A24,116CommonForm 4 ↗
Aby MathewEVP & Chief Scientific Officer2026-02-24A39,605CommonForm 4 ↗
Aby MathewEVP & Chief Scientific Officer2026-02-24A20,096CommonForm 4 ↗
Cathy CosteDirector2026-02-24A8,170CommonForm 4 ↗
Todd BerardChief Marketing Officer2026-02-24A20,096CommonForm 4 ↗
Troy WichtermanChief Financial Officer2026-02-24A64,866CommonForm 4 ↗
Tony HuntDirector2026-02-24A8,170CommonForm 4 ↗
Rachel EllingsonDirector2026-02-24A8,170CommonForm 4 ↗
Roderick de GreefDirector2026-02-24D67,010231,517,777CommonForm 4 ↗
Aby MathewEVP & Chief Scientific Officer2026-02-24D15,58523353,000CommonForm 4 ↗
Sarah AebersoldChief Human Resources Officer2026-02-24D5,73423129,875CommonForm 4 ↗
Timothy MooreDirector2026-02-24A8,170CommonForm 4 ↗
Todd BerardChief Marketing Officer2026-02-24A22,479CommonForm 4 ↗
Sarah AebersoldChief Human Resources Officer2026-02-24A23,548CommonForm 4 ↗
Troy WichtermanChief Financial Officer2026-02-24D25,52523578,141CommonForm 4 ↗
Troy WichtermanChief Financial Officer2026-02-24A31,150CommonForm 4 ↗
Todd BerardChief Marketing Officer2026-02-24D8,84623200,362CommonForm 4 ↗
Joydeep GoswamiDirector2026-02-24A8,170CommonForm 4 ↗
Karen FosterChief Quality and Operations2026-02-24D13,01323294,744CommonForm 4 ↗
Roderick de GreefDirector2026-02-24D86,186231,952,113CommonForm 4 ↗
Roderick de GreefDirector2026-02-24A219,024CommonForm 4 ↗
Roderick de GreefDirector2026-02-24A118,730CommonForm 4 ↗
Karen FosterChief Quality and Operations2026-03-03D418218,669CommonForm 4 ↗
Sean WernerChief Technology Officer2026-03-03D111212,302CommonForm 4 ↗
Troy WichtermanChief Financial Officer2026-03-03D5882112,195CommonForm 4 ↗
Aby MathewEVP & Chief Scientific Officer2026-03-03D5292110,971CommonForm 4 ↗
Todd BerardChief Marketing Officer2026-03-03D353217,321CommonForm 4 ↗
Sarah AebersoldChief Human Resources Officer2026-03-03D219214,542CommonForm 4 ↗
Karen FosterChief Quality and Operations2026-03-05D5002010,000CommonForm 4 ↗
Karen FosterChief Quality and Operations2026-03-05D96,923201,952,998CommonForm 4 ↗
Karen FosterChief Quality and Operations2026-03-19D1,9071936,462CommonForm 4 ↗
Sarah AebersoldChief Human Resources Officer2026-03-19D9311917,801CommonForm 4 ↗
Sean WernerChief Technology Officer2026-03-19D1,6811932,141CommonForm 4 ↗
Roderick de GreefDirector2026-03-19D11,10119212,251CommonForm 4 ↗
Aby MathewEVP & Chief Scientific Officer2026-03-19D2,2551943,116CommonForm 4 ↗
Todd BerardChief Marketing Officer2026-03-19D1,8791935,926CommonForm 4 ↗
Troy WichtermanChief Financial Officer2026-03-19D3,7491971,681CommonForm 4 ↗
Karen FosterChief Quality and Operations2026-03-23D2,5771949,401CommonForm 4 ↗
Todd BerardChief Marketing Officer2026-04-08D293195,646CommonForm 4 ↗
Troy WichtermanChief Financial Officer2026-04-08D8441916,264CommonForm 4 ↗
Aby MathewEVP & Chief Scientific Officer2026-04-08D515199,924CommonForm 4 ↗
Casdin Partners Master Fund, L.P.Greater-than-10% holder2026-05-19D650,0002415,405,000CommonForm 4 ↗
Casdin Partners Master Fund, L.P.Greater-than-10% holder2026-05-19D250,000245,925,000CommonForm 4 ↗
Casdin Partners Master Fund, L.P.Greater-than-10% holder2026-05-19D300,000236,795,000CommonForm 4 ↗
Troy WichtermanChief Financial Officer2026-06-08D1,0262626,779CommonForm 4 ↗
Aby MathewEVP & Chief Scientific Officer2026-06-08D6272616,365CommonForm 4 ↗
Todd BerardChief Marketing Officer2026-06-08D356269,292CommonForm 4 ↗
Troy WichtermanChief Financial Officer2026-06-18D9372624,399CommonForm 4 ↗
Todd BerardChief Marketing Officer2026-06-18D4702612,239CommonForm 4 ↗
Roderick de GreefDirector2026-06-18D2,7752672,261CommonForm 4 ↗
Sean WernerChief Technology Officer2026-06-18D4202610,937CommonForm 4 ↗
Aby MathewEVP & Chief Scientific Officer2026-06-18D5642614,687CommonForm 4 ↗
Todd BerardChief Marketing Officer2026-07-07D293288,142CommonForm 4 ↗
Aby MathewEVP & Chief Scientific Officer2026-07-07D5162814,340CommonForm 4 ↗
Troy WichtermanChief Financial Officer2026-07-07D8442823,455CommonForm 4 ↗
Sean WernerChief Technology Officer2026-07-17D275298,016CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2024

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Todd BerardPSU2024-03-0838379,904$379,904
Aby MathewPSU2024-03-0838669,352669,352
Garrie RichardsonPSU2024-03-0838434,556434,556
Garrie RichardsonPSU2024-03-08812,516217,278217,278
Aby MathewPSU2024-03-08825,470442,159442,159
Todd BerardPSU2024-03-08814,456250,956250,956
Troy WichtermanPSU2024-03-08381,096,2701,096,270
Troy WichtermanPSU2024-03-08841,715724,172724,172
Karen FosterPSU2024-03-08820,651358,501358,501
Karen FosterPSU2024-03-0838542,708542,708
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Todd Berard$0$630,860$0100.0%
Aby Mathew01,111,5110100.0%
Garrie Richardson0651,8340100.0%
Troy Wichterman01,820,4420100.0%
Karen Foster0901,2090100.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2024

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Todd BerardRSU226$5,867
Karen FosterRSU5,112132,708
Karen FosterRSU9,551247,944
Todd BerardRSU14,456375,278
Aby MathewRSU11,779305,783
Aby MathewRSU6,572170,609
Todd BerardPSU11,885308,535
Karen FosterRSU20,651536,100
Karen FosterRSU2606,750
Karen FosterPSU20,651536,100
Todd BerardRSU4,381113,731
Todd BerardRSU6,686173,569
Roderick de GreefRSU296,1427,687,846
Aby MathewPSU20,940543,602
Aby MathewPSU25,470661,201
Karen FosterPSU16,978440,749
Troy WichtermanRSU7,302189,560
Troy WichtermanRSU41,7151,082,921
Troy WichtermanPSU34,296890,324
Troy WichtermanPSU41,7151,082,921
Roderick de GreefPSU219,0245,685,863
Aby MathewRSU25,470661,201
Troy WichtermanRSU3559,216
Todd BerardPSU14,456375,278
Troy WichtermanRSU19,292500,820
Karen FosterOption100,0001.9
Aby MathewRSU3067,944
05

Incentive-plan design — the Compensation Discussion & Analysis

The Company's compensation philosophy is to provide compensation that will attract and retain high-performing talent in our industry, motivate the Company's executive officers to create long-term, enhanced stockholder value and provide a fair reward for executive effort, and stimulate professional and personal growth.

CEO STI target (% of salary)100%
CEO LTI target (% of salary)
Independent consultantFrederic W. Cook & Co, Inc.
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20252025-08-2038,403,8562,060,35284,48094.71%Passed
20242024-08-0132,528,8554,957,793203,07786.31%Passed
20232023-07-2128,011,7245,972,831204,76881.93%Passed
20222022-06-0920,068,5676,973,007127,21673.87%Passed
20212021-06-1814,145,5475,782,63522,81970.9%Passed
20202020-07-0916,218,177961,890100,48893.85%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20252025-08-2094.71%a
20242024-08-0186.31%b
20232023-07-2181.93%c

a. Approved under the standard stated in the filing — “With regard to the ratification of the appointment by our Audit Committee of Grant Thornton as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 under Proposal 3, abstentions will not be counted for purposes of determining whether such proposal has been ratified and will not have the effect of negative votes, whereas, because the ratification of the appointment of Grant Thornton is a routine matter, a broker may vote on this matter without instructions from the beneficial owner.”.

b. Approved under the standard stated in the filing — “With regard to the ratification of the appointment by our Audit Committee of Grant Thornton as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 under Proposal 3, abstentions will not be counted for purposes of determining whether such proposal has been ratified and will not have the effect of negative votes, whereas, because the ratification of the appointment of Grant Thornton is a routine matter, a broker may vote on this matter without instructions from the beneficial owner.”.

c. Approved under the standard stated in the filing — “With regard to Proposals Two and Four, abstentions and broker non-votes will not be counted for purposes of determining whether such proposal has been approved and will not have the effect of negative votes.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)58 : 1
CEO total compensation$7,046,205
Median employee compensation$122,390
08

Director compensation — fiscal year 2024

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Amy DuRossIndependent · Lead Independent Director · Compensation (Chair)$112,500$0$0$0$0$112,500
Joydeep GoswamiIndependent · Audit · Nominating/Governance (Chair)75,729000075,729
Cathy CosteIndependent · Audit (Chair)73,750000073,750
Tony HuntIndependent · Audit · Compensation60,000000060,000
Rachel EllingsonIndependent · Audit · Compensation60,000000060,000
Timothy MooreIndependent · Compensation60,000000060,000
Roderick de GreefEmployee director · Board Chair00000
09

Board fee structure and ownership guideline

Annual cash retainer$70,000
Annual equity retainer$180,000
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)13,750 / 12,500 / 10,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2024
Cash retainers and fees$441,979
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$441,979

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2024

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Biolife Solutions Inc names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Biolife Solutions Inc.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Silk Road Medical, Inc.2023Chas McKhann$105,871$13,123,059$0$93,275$13,423,834
2Glaukos2025Thomas Burns850,0007,649,9473,527,497012,034,087
3NEVRO Corporation2023Kevin Thornal515,62510,080,1730402,75011,453,548
4iRhythm2025Quentin Blackford700,0038,919,45701,350,00011,003,163
5Azenta2025John Marotta900,0008,386,29701,063,65610,371,414
6Axogen Corporation2025Michael Dale775,8657,342,8950906,1339,047,454
7Standard BioTools2025Michael Egholm680,2565,337,8831,671,3631,120,0008,823,502
8STAAR Surgical Company2025Stephen Farrell580,0006,836,000007,522,385
9Veracyte, Inc.2025Marc Stapley700,0005,890,8770826,0007,421,877
10Biolife Solutions Inc2024Roderick de Greef744,4505,571,8740655,1167,046,205
11Artivion2025J. Patrick Mackin835,1455,006,9900991,3686,883,108
12Mesa Laboratories, Inc.2026Gary Owens808,8464,700,01701,120,0006,643,208
13AngioDynamics2025James Clemmer803,0272,628,871808,2071,215,6085,494,285
14Avid Bioservices2024Nicholas Green650,0003,776,336004,475,343
15Cerus Corporation2025William Greenman793,7502,242,5850756,0003,794,657
16MaxCyte2025Maher Masoud590,0001,143,275625,300313,2902,687,657
17Cryoport2025Jerrell Shelton967,845192,300306,869908,5102,375,524
18Codexis2025Alison Moore524,732255,9941,065,223463,1252,323,279
19Seres Therapeutics2025Eric Shaff408,33301,338,87001,775,549
20Atrion Corporation2023David Battat718,07700180,000924,464

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Biolife Solutions Inc88%RSU 50 · PSU 50Yes — Total Shareholder Return (TSR)Frederic W. Cook & Co, Inc.
AngioDynamics150%PSU 50 · RSU 25 · Options 25NoMeridian Compensation Partners, LLC
Artivion118.7%PSU 50 · RSU 50NoWillis Towers Watson
Atrion Corporation25%RSU 100not disclosedFW Cook
Avid Bioservices0%PSU 50 · RSU 50NoAnderson Pay Advisors, LLC
Axogen Corporation116.79%PSU 50 · RSU 50NoAon
Azenta107.4%PSU 50 · RSU 50Yes — Relative Total Shareholder Return (rTSR)Pearl Meyer
Cerus Corporation126%RSU 75 · PSU 25NoAlpine
Codexis95%not disclosednot disclosedPearl Meyer
Cryoport92.2%Options 62 · RSU 38not disclosedFrederic W. Cook & Co., Inc.
Glaukos177.5%PSU 50NoFrederic W. Cook & Co., Inc.
iRhythm173%PSU 50 · RSU 50NoAon (January 1 to May 28) and Mercer (May 29 forward)
MaxCyte88.5%not disclosedNoPearl Meyer
Mesa Laboratories, Inc.125%PSU 50 · RSU 50NoFrederic W. Cook & Co, Inc.
NEVRO Corporation53.7%RSU 50 · PSU 50NoAon
Seres Therapeuticsnot disclosedOptions 100not disclosedAlpine Rewards, LLC
Silk Road Medical, Inc.not disclosedPSU 50 · RSU 50not disclosedCompensia
STAAR Surgical Company135%RSU 50 · PSU 50NoSemler Brossy
Standard BioTools160%not disclosednot disclosedPearl Meyer
Veracyte, Inc.118%PSU 50 · RSU 50NoAon

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

FAQ

Frequently asked questions

Who was the highest-paid executive at Biolife Solutions Inc in fiscal 2024?
The highest-paid executive at Biolife Solutions Inc in fiscal 2024 was Roderick de Greef, Chief Executive Officer and Chairman of the Board, with total compensation of $7,046,205.
How does Biolife Solutions Inc's chief executive pay compare to its disclosed peer group?
The company reported that the CEO's pay was at the 53rd percentile of disclosed peers.
What is Biolife Solutions Inc's CEO-to-median employee pay ratio?
The filing shows the CEO-to-median employee pay ratio was 58:1.
How did shareholders vote on Biolife Solutions Inc's executive compensation?
Shareholders voted 94.71% in support of the executive compensation plan.
How much does Biolife Solutions Inc spend in total on board compensation for fiscal 2024?
Total board compensation for fiscal 2024 was $441,979.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Roderick de GreefDEF 14A2025-07-080000834365-25-000007Section “Summary compensation table”. As printed: 7,046,205. Filing ↗machine: t19 · r3 · c19 · span 344908–344917
2Section 01, Troy WichtermanDEF 14A2025-07-080000834365-25-000007Section “Summary compensation table”. As printed: 2,554,007. Filing ↗machine: t19 · r11 · c19 · span 366266–366275
3Section 01, Aby MathewDEF 14A2025-07-080000834365-25-000007Section “Summary compensation table”. As printed: 1,733,494. Filing ↗machine: t19 · r7 · c19 · span 355750–355759
4Section 01, Karen FosterDEF 14A2025-07-080000834365-25-000007Section “Summary compensation table”. As printed: 1,515,139. Filing ↗machine: t19 · r19 · c19 · span 385787–385796
5Section 01, Garrie RichardsonDEF 14A2025-07-080000834365-25-000007Section “Summary compensation table”. As printed: 1,387,288. Filing ↗machine: t19 · r17 · c19 · span 381302–381311
6Section 01, Todd BerardDEF 14A2025-07-080000834365-25-000007Section “Summary compensation table”. As printed: 1,127,495. Filing ↗machine: t19 · r15 · c19 · span 376780–376789
7Section 03, Todd Berard PSUDEF 14A2025-07-080000834365-25-000007Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t20 · r14 · c20 · span 450118–450125
8Section 03, Aby Mathew PSUDEF 14A2025-07-080000834365-25-000007Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t20 · r8 · c20 · span 432853–432860
9Section 03, Garrie Richardson PSUDEF 14A2025-07-080000834365-25-000007Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t20 · r17 · c20 · span 458754–458761
10Section 03, Garrie Richardson PSUDEF 14A2025-07-080000834365-25-000007Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t20 · r18 · c20 · span 461471–461478
11Section 03, Aby Mathew PSUDEF 14A2025-07-080000834365-25-000007Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t20 · r9 · c20 · span 435566–435573
12Section 03, Todd Berard PSUDEF 14A2025-07-080000834365-25-000007Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t20 · r15 · c20 · span 452829–452836
13Section 03, Troy Wichterman PSUDEF 14A2025-07-080000834365-25-000007Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t20 · r11 · c20 · span 441488–441497
14Section 03, Troy Wichterman PSUDEF 14A2025-07-080000834365-25-000007Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t20 · r12 · c20 · span 444205–444212
15Section 03, Karen Foster PSUDEF 14A2025-07-080000834365-25-000007Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t20 · r21 · c20 · span 470098–470105
16Section 03, Karen Foster PSUDEF 14A2025-07-080000834365-25-000007Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t20 · r20 · c20 · span 467386–467393
17Section 07, pay ratioDEF 14A2025-07-080000834365-25-000007Section “CEO Pay Ratio”. As printed: 58 : 1. Filing ↗machine: span 621135–621137
18Section 08, Amy DuRossDEF 14A2025-07-080000834365-25-000007Section “Director Compensation”. As printed: 112,500. Filing ↗machine: t32 · r2 · c8 · span 714484–714491
19Section 08, Joydeep GoswamiDEF 14A2025-07-080000834365-25-000007Section “Director Compensation”. As printed: 75,729. Filing ↗machine: t32 · r4 · c8 · span 717656–717662
20Section 08, Cathy CosteDEF 14A2025-07-080000834365-25-000007Section “Director Compensation”. As printed: 73,750. Filing ↗
21Section 08, Tony HuntDEF 14A2025-07-080000834365-25-000007Section “Director Compensation”. As printed: 60,000. Filing ↗
22Section 08, Rachel EllingsonDEF 14A2025-07-080000834365-25-000007Section “Director Compensation”. As printed: 60,000. Filing ↗machine: t32 · r3 · c2 · span 715172–715178
23Section 08, Timothy MooreDEF 14A2025-07-080000834365-25-000007Section “Director Compensation”. As printed: 60,000. Filing ↗machine: r5 · c2 · span 718310–718316
24Section 08, Roderick de GreefDEF 14A2025-07-080000834365-25-000007Section “Director Compensation”. As printed: 0. Filing ↗
25Section 02, Sean Werner 2025-07-18Form 42025-07-220001628280-25-035591Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Casdin Partners Master Fund, L.P. 2025-08-11Form 42025-08-130000919574-25-004702Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Casdin Partners Master Fund, L.P. 2025-08-15Form 42025-08-210000919574-25-005051Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Todd Berard 2025-08-25Form 42025-08-270001633186-25-000003Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Sarah Aebersold 2025-08-26Form 42025-08-280001628280-25-041300Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Troy Wichterman 2025-08-26Form 42025-08-280001628280-25-041301Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Aby Mathew 2025-08-26Form 42025-08-280001628280-25-041304Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Todd Berard 2025-08-26Form 42025-08-280001628280-25-041299Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Karen Foster 2025-08-26Form 42025-08-280001628280-25-041303Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Sean Werner 2025-08-26Form 42025-08-280001628280-25-041302Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Troy Wichterman 2025-09-11Form 42025-09-150001892616-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Todd Berard 2025-09-11Form 42025-09-150001633186-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Sarah Aebersold 2025-09-11Form 42025-09-150001837756-25-000003Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Aby Mathew 2025-09-11Form 42025-09-150001556355-25-000003Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Sean Werner 2025-09-11Form 42025-09-150002047541-25-000003Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Karen Foster 2025-09-11Form 42025-09-150001683151-25-000003Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Sarah Aebersold 2025-09-15Form 42025-09-170001837756-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Troy Wichterman 2025-10-09Form 42025-10-140001628280-25-045019Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Todd Berard 2025-10-09Form 42025-10-140001628280-25-045018Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Karen Foster 2025-10-09Form 42025-10-140001628280-25-045015Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Aby Mathew 2025-10-09Form 42025-10-140001628280-25-045017Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Sarah Aebersold 2025-10-09Form 42025-10-140001628280-25-045016Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Casdin Partners Master Fund, L.P. 2025-10-15Form 42025-10-170000919574-25-006180Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Joydeep Goswami 2025-10-16Form 42025-10-200001628280-25-045544Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Sean Werner 2025-10-20Form 42025-10-220001628280-25-045913Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Roderick de Greef 2025-10-22Form 42025-10-240001628280-25-046297Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Joydeep Goswami 2025-10-24Form 42025-10-280001628280-25-046841Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Roderick de Greef 2025-11-11Form 42025-11-130001628280-25-052129Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Roderick de Greef 2025-11-11Form 42025-11-130001628280-25-052129Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Roderick de Greef 2025-11-11Form 42025-11-130001628280-25-052129Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Amy DuRoss 2025-11-19Form 42025-11-210001628280-25-053665Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Amy DuRoss 2025-11-19Form 42025-11-210001628280-25-053665Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Amy DuRoss 2025-11-19Form 42025-11-210001628280-25-053665Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Karen Foster 2025-11-25Form 42025-11-280001628280-25-054280Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Aby Mathew 2025-11-25Form 42025-11-280001628280-25-054278Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Amy DuRoss 2025-11-25Form 42025-11-280001628280-25-054285Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Sarah Aebersold 2025-11-25Form 42025-11-280001628280-25-054281Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Todd Berard 2025-11-25Form 42025-11-280001628280-25-054283Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Sean Werner 2025-11-25Form 42025-11-280001628280-25-054279Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Troy Wichterman 2025-11-25Form 42025-11-280001628280-25-054282Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Amy DuRoss 2025-11-25Form 42025-11-280001628280-25-054285Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Troy Wichterman 2025-12-04Form 42025-12-050001628280-25-055636Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Sarah Aebersold 2025-12-09Form 42025-12-170001628280-25-057722Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Karen Foster 2025-12-09Form 42025-12-170001628280-25-057719Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Troy Wichterman 2025-12-09Form 42025-12-170001628280-25-057723Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Aby Mathew 2025-12-09Form 42025-12-170001628280-25-057724Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Sarah Aebersold 2025-12-09Form 42025-12-170001628280-25-057722Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Todd Berard 2025-12-09Form 42025-12-170001628280-25-057720Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Amy DuRoss 2025-12-15Form 42025-12-170001628280-25-057721Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Karen Foster 2026-01-06Form 42026-01-080001628280-26-001385Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Aby Mathew 2026-01-06Form 42026-01-080001628280-26-001383Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Todd Berard 2026-01-06Form 42026-01-080001628280-26-001382Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Sarah Aebersold 2026-01-06Form 42026-01-080001628280-26-001384Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Troy Wichterman 2026-01-06Form 42026-01-080001628280-26-001387Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Roderick de Greef 2026-02-24Form 42026-02-260001628280-26-012474Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Karen Foster 2026-02-24Form 42026-02-260001628280-26-012469Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Amy DuRoss 2026-02-24Form 42026-02-260001628280-26-012480Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Sean Werner 2026-02-24Form 42026-02-260001628280-26-012471Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Aby Mathew 2026-02-24Form 42026-02-260001628280-26-012473Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Aby Mathew 2026-02-24Form 42026-02-260001628280-26-012473Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Cathy Coste 2026-02-24Form 42026-02-260001628280-26-012477Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Todd Berard 2026-02-24Form 42026-02-260001628280-26-012481Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Troy Wichterman 2026-02-24Form 42026-02-260001628280-26-012479Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Tony Hunt 2026-02-24Form 42026-02-260001628280-26-012478Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Rachel Ellingson 2026-02-24Form 42026-02-260001628280-26-012476Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Roderick de Greef 2026-02-24Form 42026-02-260001628280-26-012474Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Aby Mathew 2026-02-24Form 42026-02-260001628280-26-012473Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, Sarah Aebersold 2026-02-24Form 42026-02-260001628280-26-012472Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Timothy Moore 2026-02-24Form 42026-02-260001628280-26-012470Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Todd Berard 2026-02-24Form 42026-02-260001628280-26-012481Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Sarah Aebersold 2026-02-24Form 42026-02-260001628280-26-012472Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Troy Wichterman 2026-02-24Form 42026-02-260001628280-26-012479Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Troy Wichterman 2026-02-24Form 42026-02-260001628280-26-012479Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Todd Berard 2026-02-24Form 42026-02-260001628280-26-012481Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Joydeep Goswami 2026-02-24Form 42026-02-260001628280-26-012468Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Karen Foster 2026-02-24Form 42026-02-260001628280-26-012469Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Roderick de Greef 2026-02-24Form 42026-02-260001628280-26-012474Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Roderick de Greef 2026-02-24Form 42026-02-260001628280-26-012474Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Roderick de Greef 2026-02-24Form 42026-02-260001628280-26-012474Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, Karen Foster 2026-03-03Form 42026-03-050001628280-26-015341Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Sean Werner 2026-03-03Form 42026-03-050001628280-26-015342Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, Troy Wichterman 2026-03-03Form 42026-03-050001628280-26-015339Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, Aby Mathew 2026-03-03Form 42026-03-050001628280-26-015340Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Todd Berard 2026-03-03Form 42026-03-050001628280-26-015336Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Sarah Aebersold 2026-03-03Form 42026-03-050001628280-26-015337Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, Karen Foster 2026-03-05Form 42026-03-090001628280-26-016165Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, Karen Foster 2026-03-05Form 42026-03-090001628280-26-016165Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, Karen Foster 2026-03-19Form 42026-03-230001628280-26-020576Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, Sarah Aebersold 2026-03-19Form 42026-03-230001628280-26-020577Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, Sean Werner 2026-03-19Form 42026-03-230001628280-26-020579Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, Roderick de Greef 2026-03-19Form 42026-03-230001628280-26-020581Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, Aby Mathew 2026-03-19Form 42026-03-230001628280-26-020574Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, Todd Berard 2026-03-19Form 42026-03-230001628280-26-020580Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, Troy Wichterman 2026-03-19Form 42026-03-230001628280-26-020578Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, Karen Foster 2026-03-23Form 42026-03-310001628280-26-022501Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, Todd Berard 2026-04-08Form 42026-04-100001628280-26-024766Insider equity transaction reported since the proxy statement. Filing ↗
121Section 02, Troy Wichterman 2026-04-08Form 42026-04-100001628280-26-024765Insider equity transaction reported since the proxy statement. Filing ↗
122Section 02, Aby Mathew 2026-04-08Form 42026-04-100001628280-26-024767Insider equity transaction reported since the proxy statement. Filing ↗
123Section 02, Casdin Partners Master Fund, L.P. 2026-05-19Form 42026-05-210000919574-26-003646Insider equity transaction reported since the proxy statement. Filing ↗
124Section 02, Casdin Partners Master Fund, L.P. 2026-05-19Form 42026-05-210000919574-26-003646Insider equity transaction reported since the proxy statement. Filing ↗
125Section 02, Casdin Partners Master Fund, L.P. 2026-05-19Form 42026-05-210000919574-26-003646Insider equity transaction reported since the proxy statement. Filing ↗
126Section 02, Troy Wichterman 2026-06-08Form 42026-06-100001628280-26-042286Insider equity transaction reported since the proxy statement. Filing ↗
127Section 02, Aby Mathew 2026-06-08Form 42026-06-100001628280-26-042284Insider equity transaction reported since the proxy statement. Filing ↗
128Section 02, Todd Berard 2026-06-08Form 42026-06-100001628280-26-042285Insider equity transaction reported since the proxy statement. Filing ↗
129Section 02, Troy Wichterman 2026-06-18Form 42026-06-220001628280-26-044695Insider equity transaction reported since the proxy statement. Filing ↗
130Section 02, Todd Berard 2026-06-18Form 42026-06-220001628280-26-044699Insider equity transaction reported since the proxy statement. Filing ↗
131Section 02, Roderick de Greef 2026-06-18Form 42026-06-220001628280-26-044696Insider equity transaction reported since the proxy statement. Filing ↗
132Section 02, Sean Werner 2026-06-18Form 42026-06-220001628280-26-044698Insider equity transaction reported since the proxy statement. Filing ↗
133Section 02, Aby Mathew 2026-06-18Form 42026-06-220001628280-26-044694Insider equity transaction reported since the proxy statement. Filing ↗
134Section 02, Todd Berard 2026-07-07Form 42026-07-130001628280-26-048052Insider equity transaction reported since the proxy statement. Filing ↗
135Section 02, Aby Mathew 2026-07-07Form 42026-07-130001628280-26-048053Insider equity transaction reported since the proxy statement. Filing ↗
136Section 02, Troy Wichterman 2026-07-07Form 42026-07-130001628280-26-048054Insider equity transaction reported since the proxy statement. Filing ↗
137Section 02, Sean Werner 2026-07-17Form 42026-07-210001628280-26-049086Insider equity transaction reported since the proxy statement. Filing ↗
138Section 06, 2025 voteForm 8-K2025-08-210000834365-25-000018Item 5.07 · say-on-pay result. As reported: 94.71% (votes for as printed: 38,403,856). Filing ↗
139Section 06, 2024 voteForm 8-K2024-08-060001628280-24-035254Item 5.07 · say-on-pay result. As reported: 86.31% (votes for as printed: 32,528,855). Filing ↗
140Section 06, 2023 voteForm 8-K2023-07-270001628280-23-025959Item 5.07 · say-on-pay result. As reported: 81.93% (votes for as printed: 28,011,724). Filing ↗
141Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
142Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
143Section 09b board cost (computed)ComputedcomputedCash 441,979 + equity 0 + all other 0 = 441,979, summed across the director compensation table rows.machine: formula: Σ = 441,979
144Silk Road Medical, Inc., Section 10b CEO totalDEF 14A2024-04-260001397702-24-000024CEO total compensation as printed in Silk Road Medical, Inc.'s own proxy. As printed: 13,423,834. Filing ↗machine: r2 · c8 · span 1756696–1756706
145Glaukos, Section 10b CEO totalDEF 14A2026-04-160001193125-26-157829CEO total compensation as printed in Glaukos's own proxy. As printed: 12,034,087. Filing ↗machine: t93 · r6 · c38 · span 1876942–1876952
146NEVRO Corporation, Section 10b CEO totalDEF 14A2024-04-120000950170-24-044100CEO total compensation as printed in NEVRO Corporation's own proxy. As printed: 11,453,548. Filing ↗machine: r2 · c16 · span 631983–631993
147iRhythm, Section 10b CEO totalDEF 14A2026-04-170001388658-26-000030CEO total compensation as printed in iRhythm's own proxy. As printed: 11,003,163. Filing ↗machine: r2 · c21 · span 1123498–1123508
148Azenta, Section 10b CEO totalDEF 14A2025-12-180001140361-25-046064CEO total compensation as printed in Azenta's own proxy. As printed: 10,371,414. Filing ↗machine: r2 · c22 · span 1247118–1247129
149Axogen Corporation, Section 10b CEO totalDEF 14A2026-04-290000805928-26-000057CEO total compensation as printed in Axogen Corporation's own proxy. As printed: 9,047,454. Filing ↗machine: r2 · c45 · span 557309–557318
150Standard BioTools, Section 10b CEO totalDEF 14A2026-04-270001140361-26-017100CEO total compensation as printed in Standard BioTools's own proxy. As printed: 8,823,502. Filing ↗machine: r2 · c22 · span 553256–553266
151STAAR Surgical Company, Section 10b CEO totalDEF 14A2026-05-040000718937-26-000015CEO total compensation as printed in STAAR Surgical Company's own proxy. As printed: 7,522,385. Filing ↗machine: r3 · c16 · span 1045477–1045486
152Veracyte, Inc., Section 10b CEO totalDEF 14A2026-04-220001384101-26-000021CEO total compensation as printed in Veracyte, Inc.'s own proxy. As printed: 7,421,877. Filing ↗machine: r4 · c27 · span 855413–855422
153Biolife Solutions Inc (subject), Section 10b CEO totalDEF 14A2025-07-080000834365-25-000007CEO total compensation as printed in Biolife Solutions Inc's own proxy. As printed: 7,046,205. Filing ↗machine: t19 · r3 · c19 · span 344908–344917
154Artivion, Section 10b CEO totalDEF 14A2026-04-010001999371-26-007510CEO total compensation as printed in Artivion's own proxy. As printed: 6,883,108. Filing ↗machine: r3 · c9 · span 741873–741882
155Mesa Laboratories, Inc., Section 10b CEO totalDEF 14A2026-07-220000724004-26-000071CEO total compensation as printed in Mesa Laboratories, Inc.'s own proxy. As printed: 6,643,208. Filing ↗machine: r3 · c24 · span 580946–580955
156AngioDynamics, Section 10b CEO totalDEF 14A2025-09-250001628280-25-042704CEO total compensation as printed in AngioDynamics's own proxy. As printed: 5,494,285. Filing ↗machine: r2 · c27 · span 502542–502551
157Avid Bioservices, Section 10b CEO totalDEF 14A2024-08-280001683168-24-006081CEO total compensation as printed in Avid Bioservices's own proxy. As printed: 4,475,343. Filing ↗machine: r1 · c8 · span 442595–442604
158Cerus Corporation, Section 10b CEO totalDEF 14A2026-04-220001020214-26-000011CEO total compensation as printed in Cerus Corporation's own proxy. As printed: 3,794,657. Filing ↗machine: span 1301658–1301667
159MaxCyte, Section 10b CEO totalDEF 14A2026-04-290001140361-26-017844CEO total compensation as printed in MaxCyte's own proxy. As printed: 2,687,657. Filing ↗machine: r2 · c21 · span 315402–315411
160Cryoport, Section 10b CEO totalDEF 14A2026-04-220001140361-26-016129CEO total compensation as printed in Cryoport's own proxy. As printed: 2,375,524. Filing ↗machine: t277 · r2 · c22 · span 1285130–1285139
161Codexis, Section 10b CEO totalDEF 14A2026-04-280001193125-26-186994CEO total compensation as printed in Codexis's own proxy. As printed: 2,323,279. Filing ↗machine: r2 · c27 · span 319928–319937
162Seres Therapeutics, Section 10b CEO totalDEF 14A2026-04-270001193125-26-182036CEO total compensation as printed in Seres Therapeutics's own proxy. As printed: 1,775,549. Filing ↗machine: r2 · c29 · span 928055–928064
163Atrion Corporation, Section 10b CEO totalDEF 14A2024-04-090001104659-24-044922CEO total compensation as printed in Atrion Corporation's own proxy. As printed: 924,464. Filing ↗machine: r12 · c47 · span 467910–467917
164Section 10a, AngioDynamics reciprocityDEF 14A0001628280-25-042704AngioDynamics's most recent proxy was read; its disclosed peer group does not include Biolife Solutions Inc. Filing ↗
165Section 10a, iRhythm reciprocityDEF 14A0001388658-26-000030iRhythm's most recent proxy was read; its disclosed peer group does not include Biolife Solutions Inc. Filing ↗
166Section 10a, Azenta reciprocityDEF 14A0001140361-25-046064Azenta's most recent proxy was read; its disclosed peer group does not include Biolife Solutions Inc. Filing ↗
167Section 10a, Veracyte, Inc. reciprocityDEF 14A0001384101-26-000021Veracyte, Inc.'s most recent proxy was read; its disclosed peer group does not include Biolife Solutions Inc. Filing ↗
168Section 10a, Artivion reciprocityDEF 14A0001999371-26-007510Artivion's most recent proxy was read; its disclosed peer group does not include Biolife Solutions Inc. Filing ↗
169Section 10a, Glaukos reciprocityDEF 14A0001193125-26-157829Glaukos's most recent proxy was read; its disclosed peer group does not include Biolife Solutions Inc. Filing ↗
170Section 10a, Seres Therapeutics reciprocityDEF 14A0001193125-26-182036Seres Therapeutics's most recent proxy was read; its disclosed peer group does not include Biolife Solutions Inc. Filing ↗
171Section 10a, NEVRO Corporation reciprocityDEF 14A0000950170-24-044100NEVRO Corporation's most recent proxy was read; its disclosed peer group does not include Biolife Solutions Inc. Filing ↗
172Section 10a, Cerus Corporation reciprocityDEF 14A0001020214-26-000011Cerus Corporation names Biolife Solutions Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗
173Section 10a, Axogen Corporation reciprocityDEF 14A0000805928-26-000057Axogen Corporation's most recent proxy was read; its disclosed peer group does not include Biolife Solutions Inc. Filing ↗
174Section 10a, Silk Road Medical, Inc. reciprocityDEF 14A0001397702-24-000024Silk Road Medical, Inc.'s most recent proxy was read; its disclosed peer group does not include Biolife Solutions Inc. Filing ↗
175Section 10a, Standard BioTools reciprocityDEF 14A0001140361-26-017100Standard BioTools's most recent proxy was read; its disclosed peer group does not include Biolife Solutions Inc. Filing ↗
176Section 10a, Avid Bioservices reciprocityDEF 14A0001683168-24-006081Avid Bioservices's most recent proxy was read; its disclosed peer group does not include Biolife Solutions Inc. Filing ↗
177Section 10a, STAAR Surgical Company reciprocityDEF 14A0000718937-26-000015STAAR Surgical Company's most recent proxy was read; its disclosed peer group does not include Biolife Solutions Inc. Filing ↗
178Section 10a, Mesa Laboratories, Inc. reciprocityDEF 14A0000724004-26-000071Mesa Laboratories, Inc. names Biolife Solutions Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗